Journal
JOURNAL OF CONTROLLED RELEASE
Volume 219, Issue -, Pages 181-191Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2015.10.009
Keywords
Oncolytic adenovirus; Clinical trials; Cancer gene therapy; Oncolytic Ad/polymer hybrid vector; Active targeting; Tumor microenvironment targeting; Systemic administration
Funding
- National Research Foundation of Korea [2010-0029220, 2013M3A9D3045879]
- National Institutes of Health, USA [CA177932]
- National Research Foundation of Korea [2010-0029220, 2013M3A9D3045879] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
